Tilray secures landmark authorization to distribute three proprietary medical cannabis flower strains in Italy, marking its EU-GMP-certified Portugal facility’s first EU-wide product launch.
– Strategic partnership with Pharmaidea educates 12,000+ pharmacies on cannabis patient care, building infrastructure for sustainable market growth through education and compliance.
– Leveraging EU production hubs in Portugal and Canada, Tilray expands across Germany, Poland, and UK, positioning to capture 18% CAGR in Europe’s $3.2B medical cannabis market by 2030.
– First-mover advantage in Italy combined with high-margin standardized products creates regulatory moat, offering investors near-term revenue catalysts and long-term sector leadership potential.
Read more at
